Get the Stockscreener App
132.94
1.25%
1.64
Pre-market:
133.23
0.29
+0.22%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $132.94, with a volume of 5.59M.
It is up +1.25% in the last 24 hours and up +3.17% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$131.30
Open:
$131.85
24h Volume:
5.59M
Relative Volume:
0.80
Market Cap:
$231.29B
Revenue:
$42.34B
Net Income/Loss:
$13.50B
P/E Ratio:
17.24
EPS:
7.71
Net Cash Flow:
$6.66B
1W Performance:
-1.67%
1M Performance:
+3.17%
6M Performance:
+11.76%
1Y Performance:
+27.89%
1-Day Range:
$131.53
$133.84
1-Week Range:
$130.43
$136.17
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.94 | 235.23B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.17 | 157.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.78 | 148.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
81.18 | 110.72B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.22 | 45.66B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T - TradingView
Cardiac Implants Market Is Booming Worldwide | Abbott - openPR.com
Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio - Yahoo
Abbott Stakes Claim in TMVR Market with New FDA Approval - Medical Device and Diagnostic industry
Top Stock Reports for Coca-Cola, Abbott & AT&T - TradingView
Abbott Laboratories’ SWOT analysis: diversified portfolio bolsters stock amid challenges - Investing.com
FDA approves self-expanding Tendyne TMVR device from Abbott - Cardiovascular Business
Abbott wins approval for open-heart surgery-free valve replacement - Crain's Chicago Business
Biochips Market Poised Boom | Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc - openPR.com
Abbott Labs (ABT) Receives FDA Approval for Tendyne Heart Valve System - GuruFocus
FDA approves Abbott mitral valve replacement device that doesn't require open-heart surgery - MassDevice
Abbott gets FDA nod for Tendyne valve for mitral valve disease - Seeking Alpha
Abbott Says Tendyne Transcatheter Mitral Valve Replacement System Receives FDA Approval - marketscreener.com
Abbott’s Tendyne valve gets FDA nod for mitral replacement By Investing.com - Investing.com Canada
Abbott (ABT) Receives FDA Approval for Tendyne Heart Valve System | ABT Stock News - GuruFocus
Abbott’s Tendyne valve gets FDA nod for mitral replacement - Investing.com
Oman Dietary Supplements Market Forecast Report to 2030, with Profiles of Nature's Way, Amway, Pfizer Gulf, Abbott Laboratories, Herbalife Nutrition, Nestle & Oman Pharmaceutical Products - GlobeNewswire
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story - Seeking Alpha
If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Abbott Laboratories (ABT) Benefitted From Better Execution - MSN
STHS unveils groundbreaking lab upgrade from Abbott at St. Tammany Parish Hospital - an17.com
Abbott Laboratories (NYSE:ABT) Collaborates On Advanced Diabetes Management With Glucose-Ketone Sensor Integration - simplywall.st
Abbott Laboratories (ABT) was up 16% in Q1 - Insider Monkey
Was Jim Cramer Right About Abbott Laboratories (ABT)? - MSN
2 Dividend Stocks to Buy With $500 and Hold Forever - The Motley Fool
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
From Acquisition to Advantage: Abbott's Growth in Heart Care - Yahoo Finance
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Yahoo Finance
Researchers question reliability of Abbott’s rapid malaria tests - Science | AAAS
Senseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott Laboratories - Nasdaq
Senseonics Secures Massive $77.8M Funding Boost as Abbott Backs Next-Gen Diabetes Monitor Launch - Stock Titan
The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott (NYSE:ABT) - Seeking Alpha
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Do Abbott Laboratories' (NYSE:ABT) Earnings Warrant Your Attention? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1 - Insider Monkey
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Biotechnology Market Set to Witness Significant Growth by 2025-2032 | Abbott Laboratories, Amgen Inc., - EIN News
United States Generic Drugs Market Forecast and Company Analysis Report 2025-2033 Featuring Teva Pharma, Aurobindo Pharma, Sun Pharma, Abbott Laboratories, Lupin Pharma, Viatris, Sandoz, Dr. Reddy'sResearchAndMarkets.com - FinancialContent
Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes - MSN
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs - Zacks Investment Research
Abbott and Epic Collaborate to Streamline Glucose Data Access for Providers - The Healthcare Technology Report.
Abbott Laboratories' segment revenues from 2017 to 2024 - Statista
3 Magnificent Stocks That Are Passive Income Machines - The Globe and Mail
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
North America Weight Management Products Market Report 2025-2033 Featuring Abbott, Nestle, Herbalife, Woodbolt, Premier Nutrition, Iovate, Kellogg, Ultimate Nutrition, Simply Good Foods, GlanbiaResearchAndMarkets.com - FinancialContent
United States Nutraceuticals Market Forecast Report 2025-2033 Featuring PepsiCo, General Mills, Nestle, Kellogg, Herbalife, Danone, Now Foods, Alticor, Red Bull, and Abbott Laboratories - GlobeNewswire
Europe Meal Replacement Products Market Forecast Report 2025-2033 Featuring Abbott Laboratories, Amway, Herbalife, The Simply Good Foods Co, Nestle, Peeroton, Huel, THG, USN, and Abnormal - Yahoo
Abbott India rises after Q4 PAT jumps 28% YoY to Rs 367 cr; declares dividend of Rs 475 /sh - Business Standard
Abbott studies show CGM users have fewer hospitalizations - BioWorld MedTech
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):